Literature DB >> 14501358

Longitudinal evaluation of apparent diffusion coefficient in children with neurofibromatosis type 1.

Shams F Sheikh1, Wayne S Kubal, Adam W Anderson, Pradeep Mutalik.   

Abstract

OBJECTIVES: Foci of T2-prolongation in both supra- and infratentorial brain in neurofibromatosis type-1 (NF1) patients have been called hamartoma-like NF1 lesions (HLL); however, their behavior is not consistent with this definition. Diffusion-weighted imaging has been used to study structure and cellularity of intracranial lesions. We applied this technique to characterize HLL as they change with time in pediatric patients.
METHODS: We retrospectively studied 12 children (ages 2-20 years) with proven NF1. Forty lesions were studied longitudinally on multiple exams for a total of 166 measurements. Apparent diffusion coefficients (ADCs) were also obtained from a comparison group comprising 14 normal children (ages 2-16 years).
RESULTS: The ADC for the lesions was generally greater than normal brain. Both supra- and infratentorial lesions had increasing ADC with patient age. This is contrasted to our comparison group of normal subjects who showed decreasing ADC with age. Linear regression analysis of infratentorial lesions yielded a slope of 2.70 x 10(-6) mm2 x s(-1) x year(-1) versus a slope of 17.57 x 10(-6) mm2 x s(-1) x year(-1) for supratentorial lesions.
CONCLUSIONS: Our observed increase in ADC of lesions in pediatric patients with NF1 suggests increasing water in the extracellular space and/or decreasing cellularity with patient age. This change may be due to increased number or size of myelin vacuoles in NF1 lesions. Supratentorial lesions had a statistically significant increase in the rate of change of ADC compared with infratentorial lesions which may reflect an intrinsic difference in the lesion or similar lesions expressed in different environments.

Entities:  

Mesh:

Year:  2003        PMID: 14501358     DOI: 10.1097/00004728-200309000-00004

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  7 in total

1.  Corpus callosum morphology and microstructure assessed using structural MR imaging and diffusion tensor imaging: initial findings in adults with neurofibromatosis type 1.

Authors:  E L Wignall; P D Griffiths; N G Papadakis; I D Wilkinson; L I Wallis; O Bandmann; P E E Cowell; N Hoggard
Journal:  AJNR Am J Neuroradiol       Date:  2010-03-18       Impact factor: 3.825

2.  Diffusion tensor imaging of neurofibromatosis bright objects in children with neurofibromatosis type 1.

Authors:  Gulhan Ertan; Elcin Zan; David M Yousem; Can Ceritoglu; Aylin Tekes; Andrea Poretti; Thierry A G M Huisman
Journal:  Neuroradiol J       Date:  2014-09-25

Review 3.  Pediatric brain MRI in neurofibromatosis type I.

Authors:  Hans-J Mentzel; Jörg Seidel; Clemens Fitzek; Annegret Eichhorn; Susanna Vogt; Jürgen R Reichenbach; Felix Zintl; Werner A Kaiser
Journal:  Eur Radiol       Date:  2004-07-29       Impact factor: 5.315

4.  Role of new magnetic resonance imaging modalities in diagnosis of orbital masses: a clinicopathologic correlation.

Authors:  Nader Roshdy; Maha Shahin; Hanem Kishk; Sherif El-Khouly; Amany Mousa; Iman Elsalekh
Journal:  Middle East Afr J Ophthalmol       Date:  2010-04

5.  Contribution of diffusion tensor MR imaging in detecting cerebral microstructural changes in adults with neurofibromatosis type 1.

Authors:  S L Zamboni; T Loenneker; E Boltshauser; E Martin; K A Il'yasov
Journal:  AJNR Am J Neuroradiol       Date:  2007-04       Impact factor: 3.825

6.  Assessment of Auditory Pathways Using Diffusion Tensor Imaging in Patients with Neurofibromatosis Type 1.

Authors:  Sedat Meydan; Sinem Aydin; Hafize Otcu; Serkan Kitis; Alpay Alkan
Journal:  Curr Med Imaging Rev       Date:  2019

7.  Alterations in white matter microstructure in neurofibromatosis-1.

Authors:  Katherine H Karlsgodt; Tena Rosser; Evan S Lutkenhoff; Tyrone D Cannon; Alcino Silva; Carrie E Bearden
Journal:  PLoS One       Date:  2012-10-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.